Research Peptides · Cat. 019-25
[D-Phe11, His12]-Sauvagine (11-40) Antagonist / Anti-Sauvagine-30 (A-Svg-30)
Supplied as 100 µg per unit. Purity ≥ 95%. Molecular weight 3650.29. Species: Other species. Technical values shown are imported catalog fields and should be confirmed against current documentation. Laboratory research use only.
Specifications
| Catalog number | 019-25 |
|---|---|
| Product type | Research Peptides |
| Peptide family | Sauvagine |
| Species | Other species |
| Unit size | 100 µg |
| Molecular weight | 3650.29 Da |
| Purity | ≥ 95% |
| Validation | Exhibits correct molecular weight |
| Appearance | White powder |
| Contents | Each vial contains 100 µg of NET peptide. Antagonism of corticotrophin-releasing factor receptors in the fourth ventricle modifies responses to mild but not restraint stress. Miragaya et al. Am J Physiol Regul Integr Comp Physiol. 2008 Aug;295(2):R404-16. Wood creosote prevents CRF-induced motility via 5-HT3 receptors in proximal and 5-HT4 receptors in distal colon in rats. Ataka et al. Auton Neurosci. 2007 May 30;133(2):136-45. Corticotropin-Releasing Hormone Receptor (CRHR)1 and CRHR2 Are Both Trafficking and Signaling Receptors for Urocortin. Tu et al. Mol Endocrinol. 2007 Mar;21(3):700-11. Urocortin 1 in the dorsal raphe regulates food and fluid consumption, but not ethanol preference in C57BL/6J mice. Weitemier et al. Neuroscience. 2006;137(4):1439-45. Corticotropin-releasing hormone and urocortin induce secretion of matrix metalloproteinase-9 (MMP-9) without change in tissue inhibitors of MMP-1 by cultured cells from human placenta and fetal membranes. Li et al. J Clin Endocrinol Metab. 2005 Dec;90(12):6569-74. Modulation of feeding-related peptide/protein signals by the blood-brain barrier. Pan et al. J Neurochem. 2004 Jul;90(2):455-61. Selective activation of corticotropin-releasing factor-2 receptors on neurochemically identified neurons in the rat dorsal raphe nucleus reveals dual actions. Pernar et al. J Neurosci. 2004 Feb 11;24(6):1305-11. |
| Solubility | Soluble in water |
| Intended use | In vitro laboratory research only — not for human or veterinary use, diagnostic or therapeutic purposes |
Sequence
D-Phe-His-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH2
Storage & handling
Up to 6 months in lyophilized form at 0-5°C. For best results, rehydrate just before use. After rehydration, keep solution at +4°C for up to 5 days or freeze at -20°C for up to 3 months. Aliquot before freezing to avoid repeated freeze-thaw cycles.
Confirm handling and preparation requirements against current product documentation and the requirements of your laboratory protocol.
Frequently asked
What is [D-Phe11, His12]-Sauvagine (11-40) Antagonist / Anti-Sauvagine-30 (A-Svg-30)?
What purity is listed for 019-25?
How should [D-Phe11, His12]-Sauvagine (11-40) Antagonist / Anti-Sauvagine-30 (A-Svg-30) be stored?
What is the sequence of [D-Phe11, His12]-Sauvagine (11-40) Antagonist / Anti-Sauvagine-30 (A-Svg-30)?
What is the intended use of 019-25?
This page reproduces an imported research-catalog record. Verify identity, specifications, documentation and suitability before purchase. The item is offered only for laboratory research and is not represented for human or veterinary use.